MIR100

Summary

MIR100 (microRNA 100, HGNC:31487) is a microRNA gene on chromosome 11q24.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406892 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31487
Approved symbol	MIR100
Name	microRNA 100
Location	11q24.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-100
Ensembl gene	ENSG00000207994
Ensembl biotype	miRNA
OMIM	613186
Entrez	406892
RNAcentral	URS000054969A — miRNA, 80 nt, 7 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385259

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385259 — 1 exons

Exon	Start	End
ENSE00001500265	122152229	122152308

Expression profiles

Bgee: expression breadth broad, 48 present calls, max score 83.15.

Top tissues by expression

48 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	83.15	gold quality
renal glomerulus	UBERON:0000074	82.54	gold quality
adrenal tissue	UBERON:0018303	80.44	gold quality
midbrain	UBERON:0001891	78.25	gold quality
monocyte	CL:0000576	77.22	gold quality
blood	UBERON:0000178	75.17	gold quality
fundus of stomach	UBERON:0001160	75.12	gold quality
stomach	UBERON:0000945	74.33	gold quality
endometrium	UBERON:0001295	73.46	gold quality
body of stomach	UBERON:0001161	73.29	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	71.93	gold quality
uterus	UBERON:0000995	68.99	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	68.58	gold quality
right atrium auricular region	UBERON:0006631	67.56	gold quality
intestine	UBERON:0000160	66.68	gold quality
small intestine Peyer’s patch	UBERON:0003454	66.27	gold quality
lower esophagus muscularis layer	UBERON:0035833	65.90	gold quality
ascending aorta	UBERON:0001496	65.63	gold quality
thoracic aorta	UBERON:0001515	65.58	gold quality
right ovary	UBERON:0002118	65.50	gold quality
omental fat pad	UBERON:0010414	65.37	gold quality
myometrium	UBERON:0001296	65.31	gold quality
ovary	UBERON:0000992	64.78	gold quality
tibial artery	UBERON:0007610	64.75	gold quality
tibial nerve	UBERON:0001323	64.64	gold quality
esophagus mucosa	UBERON:0002469	64.45	gold quality
prostate gland	UBERON:0002367	64.23	gold quality
left lobe of thyroid gland	UBERON:0001120	64.03	gold quality
minor salivary gland	UBERON:0001830	63.97	gold quality
anterior cingulate cortex	UBERON:0009835	63.76	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.48

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Down-regulation of miR-100 is associated with prostate cancer metastasis. (PMID:19372056)
• underexpressed miR-100 leads to Plk1 overexpression, which in turn contributes to nasopharyngeal cancer progression. (PMID:19739117)
• in clear cell ovarian cancer cells, overexpression of mir-100 inhibited mTOR signaling & enhanced sensitivity to RAD001; experiments revealed strong candidate miRNAs & their target genes that may contribute to pathogenesis of clear cell ovarian cancer (PMID:20081105)
• ATM is a target of miR-100 (PMID:20869334)
• 3 targets of miR-99 family (miR-99a, -99b, -100) were SMARCA5, SMARCD1, mTOR; PSA is regulated by miR-99 family, at least partially, by repression of SMARCA5; suggests key functions and targets of miR-99 family in prostate cancer suppression and prognosis (PMID:21212412)
• Reduced miR-100 expression participates in the development of cervical cancer at least partly through loss of inhibition to target gene PLK1. HR-HPV E6/E7 may not directly regulate miR-100 expression in cervical cells. (PMID:21636267)
• identified RBSP3, a phosphatase-like tumor suppressor, as a bona fide target of miR-100 and validated that RBSP3 was involved in cell differentiation and survival in acute myeloid leukemia (PMID:21643017)
• Data show that Differentially expressed miRNAs including miR-99a, miR-100, miR-125b, miR-192, and miR-429 were detected in pancreatic cancer stem cells. (PMID:21785383)
• Higher expression levels of miR-100 is associated with childhood acute lymphoblastic leukemia. (PMID:22099053)
• Data suggest that down-regulation of miR-100 could lead to Plk1 over-expression and eventually to docetaxel chemoresistance of lung adenocarcinoma. (PMID:22120675)
• Low miR-100 expression may be an independent poor prognostic factor and miR-100 can function as a tumor suppressor by targeting PLK1 in human epithelial ovarian cancer. (PMID:22246341)
• Data indicate that miR-100 reduction was paralleled by an increased expression of polo like kinase 1 (PLK1). (PMID:22249248)
• overexpression of miR-100 in bladder carcinoma cells significantly inhibited growth; study demonstrated effects of miR-100 in growth cell rates and clonogenicity capacity in 5637 cell line, emphasizing a possible effect of this miRNA in bladder carcinoma pathogenesis (PMID:22393979)
• miR-100 plays a negative role in osteogenic differentiation and might act through targeting BMPR2 (PMID:22684006)
• Explored deregulation of miRNAs targeting mTOR kinase (miR-99a, miR-100 and miR-199b) in endometrioid endometrial carcinoma. mTOR kinase expression was increased in EEC tissues and was accompanied by decreased expression of all three miRNAs. (PMID:22920721)
• Our data add IGF2 in breast cancer to the list of cancer-relevant miR-100 targets (PMID:22926517)
• MiR-100 mimics could significantly inhibit PLK1 mRNA and protein expression. (PMID:23151088)
• Reduced microRNA-100 expression may be independently associated with shorter progression-free survival and overall survival of bladder cancer patients. (PMID:23173870)
• results indicated that miR-99a and miR-100 inhibited cell proliferation by suppressing mTOR in esophageal squamous cell carcinoma cell lines (PMID:23292834)
• MiR-100 antagonism enhances graft-versus-host disease. (PMID:23327924)
• The regulation of IGF1 receptor expression by microRNA-100 in metatstatic and nonmetastatic pancreatic tumor cell lines is reported. (PMID:23373509)
• Our data offer convincing evidence that miR-100 overexpression strongly associates with advanced tumor progression and unfavorable clinical outcome of patients with RCC (PMID:23378187)
• Data suggest that acute myeloid leukemia (AML) subtypes could be distinguished by by differentially expressed miRNAs including miR-126, -146a, -181a/b, -100, and miR-125b. (PMID:23418555)
• Loss of miR100 expression is associated with prostate cancer (PMID:23503652)
• Expression of miR-100 inhibits the migration and invasion of gastric cancer cells without significant alteration of proliferation. Therefore, miR-100 might play an inhibitory role in the progression of gastric carcinoma. (PMID:23611267)
• members of miR-99 family (miR-99a, miR-99b, miR-100) were expressed during dermal wound healing. (PMID:23724047)
• Hypoxia, in part via suppression of miR-100, induces FGFR3 expression in bladder cancer, both of which have an important role in maintaining cell viability under conditions of stress. (PMID:23778527)
• Downregulation of miR-100 was correlated with progressive pathological feature and poor prognosis in hepatocellular carcinoma patients. (PMID:23842624)
• MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. (PMID:23915977)
• MiR-100 and miR-99a have critical roles in altering cellular processes by targeting both the FKBP51 and IGF1R/mTOR signalling pathways in ALL. (PMID:24030073)
• Downregulation of miR-100-3p is correlated with the presence of vascular invasion in vulvar carcinoma. (PMID:24048714)
• we consider that miR-100 acts as a tumor suppressor for osteosarcoma. (PMID:24317814)
• HOXA1-mediated SCLC chemoresistance is under the regulation of miR-100. HOXA1 may be a prognostic predictor and potential therapeutic target in human SCLC (PMID:24559685)
• Reduced miR-100 expression is associated with drug resistance in chondrosarcoma. (PMID:24568519)
• miR-100 downregulates E-cadherin by targeting SMARCA5, a regulator of CDH1 promoter methylation, this miRNA suppresses tumorigenesis, cell movement and invasion in vitro and in vivo through direct targeting of HOXA1. (PMID:24586203)
• miR-100 plays a tumor suppressor role by regulating colorectal cancer cell growth and invasion phenotype, and could serve as a potential maker for colorectal cancer therapy. (PMID:24626817)
• Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of miR-100, miR-222, and miR30a. (PMID:24740415)
• Data show that MiR-100 negatively regulates migration, invasion and epithelial-mesenchymal transition in prostate cancer cells. (PMID:24805183)
• Data uncover a new regulatory mechanism of autophagy and a novel function of miR-100 in liver neoplasms. (PMID:25026290)
• Authors have identified microRNAs-99a/100 mediate a direct relationship between FGFR3 and FOXA1 and potentially facilitate cross talk between these pathways in UCC. (PMID:25071007)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir100-2	ENSDARG00000081453
danio_rerio	mir100-1	ENSDARG00000081501
mus_musculus	Mir100	ENSMUSG00000093011
rattus_norvegicus	Mir100	ENSRNOG00000035502

Paralogs (7): MIR99B (ENSG00000207550), MIR99A (ENSG00000207638), MIR10B (ENSG00000207744), MIR125B2 (ENSG00000207863), MIR125B1 (ENSG00000207971), MIR125A (ENSG00000208008), MIR10A (ENSG00000284038)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.